Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults
Conditions: Pandemic Influenza; Influenza A Virus Infection; Orthomyxoviridae InfectionsInterventions: Biological: A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant; Biological: A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant; Biological: A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant; Biological: A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant; Biological: A/H5N1 inactivated, split-virion influenza vaccineSponsors: Sanofi; Sanofi Pasteur, a Sanofi CompanyCompleted - verified January 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bird Flu | Bird Flu (H5N1 Avian Influenza) Vaccine | Flu Pandemic | H5N1 | Influenza | Influenza Vaccine | Pandemics | Research | Vaccines